ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

Journal of Virology

Volumn 76, Issue 1, 2002, Pages 292-302

  Pal, R ^a   Venzon, D ^a   Letvin, N L ^a   Santra, S ^a   Montefiori, D C ^a   Miller, N R ^a   Tryniszewska, E ^a   Lewis, M G ^a   VanCott, T C ^a   Hirsch, V ^a   Woodward, R ^a   Gibson, A ^a   Grace, M ^a   Dobratz, E ^a   Markham, P D ^a   Hel, Z ^a   Nacsa, J ^a   Klein, M ^a   Tartaglia, J ^a   Franchini, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC SIV GPE; CD8 ANTIGEN; GAG PROTEIN; GLYCOPROTEIN GP 120; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL; T LYMPHOCYTE ACTIVATION; VACCINATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; HISTOCOMPATIBILITY ANTIGENS CLASS I; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0036133208     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.1.292-302.2002     Document Type: Article

References (56)

1. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques
2. CDS(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: Implications for vaccine design and testing
3. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canary, pox (ALVAC) vaccine candidate in cynomolgus monkeys
4. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
5. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
6. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
7. mac251: Dependence on route of challenge exposure
8. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
9. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
10. Immune responses to human immunodeficiency virus (HIV) type I induced by canarypox expressing HIV-1MN gp120, HIV-ISF2 recombinant gp120, or both vaccines in seronegative adults
11. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
12. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
13. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
14. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses
15. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques
16. Human safety and immunogenicity of a canarypoxrabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
17. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
18. 251 infection of macaques
19. + T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques
20. Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj
21. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
22. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques
23. Chimeric SHIV that causes CD4+ T cell loss and AIDS in rhesus macaques
24. Detection of intracellular antigen-specific cytokines in human T cell populations
25. Characterization of the secreted, native gp120 and gp16O of the human immunodeficiency virus type 1
26. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study
27. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
28. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
29. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys
30. Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys
31. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus
32. Containment of simian immunodeficieney virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
33. Control of SIV rebound through structured treatment interruptions during early infection
34. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
35. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
36. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease
37. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
38. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys
39. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection
40. HIV-1 Gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides
41. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
42. Major expansion of CD8+ T cells with a predominant V beta usage during the primary, immune response to HIV
43. Methodology of using vaccinia virus to express foreign genes in tissue culture
44. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases
45. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
46. Viral load and heterosexual transmission of human immunodeficiency virus type 1
47. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
48. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology
49. Immune control of HIV-1 after early treatment of acute infection
50. Sexual transmission of HIV
51. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gpl20 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
52. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
53. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
54. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
55. Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment
56. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease